Form 4: Gilead CFO Andrew Dickinson Executes Stock Sale

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock.
• The transaction occurred on May 15, 2026, at a price of $132.27 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
• Following this transaction, the reporting person maintains beneficial ownership of 173,191 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 program, which is standard practice for executive financial planning.

Positives

• The transaction was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without concerns regarding insider trading.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• None identified in this filing.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under Rule 10b5-1 plans are routine corporate governance events and generally do not signal a change in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for C-suite executives at large-cap pharmaceutical companies to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• None mentioned.

Key Dates

Keywords

Gilead Sciences, GILD, Insider Trading, Form 4, CFO, Stock Sale